+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry



Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry



Journal of Rheumatology 37(12): 2566-2572



To compare disease activity, radiographic features, and bone density in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) matched cohorts. Disease activity and radiographic data in the Consortium of Rheumatology Researchers of North America database from 2001 to 2008 were compared for 2481 patients with PsA and 17,107 patients with RA subsequently matched for age, gender, and disease duration. Radiographic outcomes included presence of erosions, and joint deformity. In addition, bone mineral density (BMD) scores for lumbar spine (L-spine) and femoral neck were compared using the same matching criteria plus weight and smoking status. Tender (4.5 vs 3.4, p < 0.001) and swollen (4.4 vs 2.9, p < 0.012) joint counts, and modified Health Assessment Questionnaire scores were significantly higher (0.4 vs 0.3, p < 0.001) in patients with RA compared with patients with PsA. Patient general health and pain scores were also higher in patients with RA vs patients with PsA. Joint erosions (47.4% vs 37.6%, p = 0.020) and deformity (25.2% vs 21.6%, p = 0.021) were more prevalent in RA than PsA. In multivariate analysis, a reduced prevalence of erosions in PsA vs RA was noted (OR 0.609, p < 0.001). After matching, T-scores for L-spine (-0.54 vs -0.36, p = 0.077) and femoral neck (-0.88 vs -0.93, p = 0.643) were similar in patients with RA and patients with PsA, although body weight was a major confounder. The level of disease activity and radiographic damage was significantly higher for RA vs PsA subjects, although the magnitude of differences was relatively small. BMD levels were comparable between cohorts. Outcomes in patients with PsA and patients with RA may be more similar than previously reported.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052208727

Download citation: RISBibTeXText

PMID: 20843908

DOI: 10.3899/jrheum.100483


Related references

AB1368Insights from a routine care rheumatoid arthritis registry in turkey (TRAV): A third of rheumatoid arthritis patients are in remission/low disease activity and 1/5 are on biologic agents. Annals of the Rheumatic Diseases 71(Suppl 3): 716.3-716, 2013

Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis. Arthritis Research and Therapy 20(1): 82, 2018

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis. Clinical Rheumatology 37(8): 2275-2280, 2018

OP0277Effect of Disease Modifying Drugs on Bone Mineral Density in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, and Ankylosing Spondylitis: A Meta-Analysis. Annals of the Rheumatic Diseases 73(Suppl 2): 166.2-167, 2014

THU0604Disease Activity and Biologic Use in Patients with Rheumatoid Arthritis and Psoriatic Arthritis in The Past 10 Years: Results from The Corrona Registry. Annals of the Rheumatic Diseases 75(Suppl 2): 410.2-411, 2016

AB0930DAREA/DAPSA (disease activity score for reactive arthritis/disease activity index for psoriatic arthritis) and related variables in patients with psoriatic arthritis (PSA):. Annals of the Rheumatic Diseases 71(Suppl 3): 691.18-691, 2013

SAT0403Further Analysis of Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) Using Data from A Placebo-Controlled TRIAL of Certolizumab Pegol in Psoriatic Arthritis. Annals of the Rheumatic Diseases 73(Suppl 2): 740.1-740, 2014

Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registry. Joint Bone Spine 80(2): 160-164, 2013

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. Current Medical Research and Opinion 2019: 1-11, 2019

Association of Body Mass Index Categories with Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis: A Systematic Review and Metaanalysis. Journal of Rheumatology 42(12): 2261-2269, 2015

Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry. Rheumatology 55(2): 286-290, 2016

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?. Annals of the Rheumatic Diseases 77(12): 1736-1741, 2018

AB0172Assessment of disease activity in rheumatoid arthritis by routine assessment of rheumatoid arthritis disease activity index (radai) and its relation with disease activity score 28 (das28), clinical disease activity index (cdai) and simplified disease acti. Annals of the Rheumatic Diseases 72(Suppl 3): A838.1-A838, 2013

Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases. Arthritis Research and Therapy 18: 149, 2016

The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si. Clinical Rheumatology 38(2): 297-305, 2019